The US Army has asked companies to bid for contracts to produce large quantities of anthrax and equipment to produce other unnamed biological agents, according to New Scientist, but has not said what it needs the facilities for.
Alan Pearson, programme director for biological and chemical weapons at the Center for Arms Control and Non-Proliferation in Washington DC, says the contracts raise serious questions about the US' commitment to the Biological Weapons Convention.
Anti-biological weapons campaigner Edward Hammond of the Sunshine Project discovered the contracts, which were issued this year.
One contract specifies: "The company must have the ability and be willing to grow Bacillus anthracis Sterne strain at 1500-litre quantities." Others call for a 3,000-litre production capacity for unnamed biological agents and sheep carcasses to investigate incineration of infected animals.
The non-virulent Sterne strain of the bacterium is the only one specified in any of the documents. It is not thought to be harmful to humans, and is used in vaccination. However, the same equipment could easily be put to use to grow spores of the lethal Ames strain, and it is this that has raised eyebrows.
Speaking to New Scientist, Hammond asked: "What would happen to the Biological Weapons Convention if other countries followed suit and built large biological production facilities at secretive military bases known for weapons testing?"
The tenders were issued by the US army's Dugway Proving Ground in Utah. Dugway maintains that the contracts are still at the "pre-solicitation" phase, and that there is currently no Anthrax at the base.
Dugway has refused to elaborate on what it needs the anthrax for, and although there is no suggestion that the US intends to restart its biological weapons programme, Hammond argues that the military might want to use the agent to test biological weapons delivery systems, for threat assessment. ®